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ABSTRACT 
MULTIPURPOSE TENOFOVIR DISOPROXIL FUMARATE ELECTROSPUN 
FIBERS FOR THE PREVENTION OF HIV-1 AND HSV-2 INFECTIONS 
 
Kevin Tyo 
 
 
 
 
Sexually transmitted infections affect hundreds of millions of worldwide. Both 
human immunodeficiency virus (HIV-1 and -2) and herpes simplex virus-2 (HSV-
2) remain incurable, urging the development of new prevention strategies. While 
current prophylactic technologies are dependent on strict user adherence to 
achieve efficacy, there is a dearth of delivery vehicles that provide discreet and 
convenient administration, combined with prolonged-delivery of active agents.  
To address these needs, we created electrospun fibers (EFs) comprised of FDA-
approved polymers, poly(lactic-co-glycolic acid) (PLGA) and  poly(DL-lactide-co-
ε-caprolactone)  (PLCL), to provide sustained-release and in vitro protection 
against HIV-1 and HSV-2. PLGA and PLCL EFs, incorporating the antiretroviral, 
tenofovir disoproxil fumarate (TDF), exhibited sustained-release for up to 4 
weeks, and provided complete in vitro protection against HSV-2 and HIV-1 for 24 
hr and 2 wk, respectively. In vitro tests confirmed the safety of these fibers in 
vaginal and cervical cells, highlighting the potential of polymeric EFs as 
multipurpose next-generation drug delivery vehicles. 
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BACKGROUND AND INTRODUCTION 
 
Sexually transmitted infections (STIs) are a global health challenge, with 
over one million new cases of STIs reported daily. Over 530 and 36 million 
people globally are infected by herpes simplex virus type-2 (HSV-2) and human 
immunodeficiency virus (HIV), respectively [1]. Compounding these statistics, 
HSV-2 infection has been shown to significantly enhance HIV infection by as 
much as 2 to 7-fold [2, 3]. Furthermore, co-infected individuals harbor higher 
concentrations of both viruses relative to individuals with only one infection [3]. 
Despite the existence of multiple strategies to prevent STIs, no cure exists for 
these diseases, and rates of infection among particular demographics remain 
high [4, 5]. 
The first known incidence of HIV infection originated in the late 1950s in 
what is today known as the Democratic Republic of the Congo [6]. The general 
consensus of scientists is that HIV originated from cross-species contamination 
of simian immunodeficiency viruses (SIVs), which normally infect primates. The 
first known cases of the current HIV pandemic in the United States date back to 
1981, where previously healthy homosexual men began suffering and dying from 
opportunistic infections [7]. At first this emerging disease, designated Acquired 
Immune Deficiency Syndrome (AIDS) was widely believed to only affect 
homosexuals. However, in 1984 it was discovered that AIDs is caused by the 
HIV, which is transmitted by hetero- and homosexual intercourse, blood-to-blood 
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transmission, or mucosal exposure [8]. Today, over 36 million people worldwide 
carry the virus, with women in the developing world bearing the highest burden of 
infection (Figure 1). 
Currently, there two types of HIV known: HIV-1 and HIV-2, with HIV-1 
being more prevalent due to higher virulence [9].  Considering genetic variability, 
HIV-1 can be further divided into three groups: major (M), outlier (O), and new 
(N) [10]. Currently, HIV-1 group M is the most prominent group and can be 
further divided by subtypes (clades). These clades, designated A-K, vary in 
incidence depending on location. In North America, clade B predominates, 
whereas in Africa clade C is the most common form of infection [11]. This sheer 
genetic variability of HIV, more thoroughly discussed in [12, 13], contributes to 
the challenges in curing HIV. 
Despite the plethora of HIV subtypes, all viral particles share the same 
general structure. At its genetic and structural levels, each HIV particle is 
comprised of two single stranded RNAs enclosed within a capsule comprised of 
p24 proteins [14]. Proteins such as reverse transcriptase and integrase are also 
enveloped within the capsule, which contains glycoproteins 120 (gp120) and 41 
(gp41). These two glycoproteins comprise the viral envelope (Env) protein and 
are essential for cellular infection.  
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Figure 1.  A heat map depicting the prevalence of HIV infection. The developing 
world is afflicted by higher rates of infection.  Additionally, women in these areas 
are more susceptible to infection. Image taken from the World Health 
Organization’s website [15].  
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HIV utilizes gp120 and gp41 to infect cells expressing the CD4 receptor as 
well as chemokine receptor 5 (CCR5) or chemokine receptor type 4 CXCR4) 
[16]. Once inside the body, HIV selectively targets CD4 T-helper cells, dendritic 
cells, macrophages, as well as Langerhans cells. Broadly, the envelope 
glycoproteins bind to the CD4 receptor [17] causing a conformational change in 
the virus envelope. This conformation triggers additional binding to either CCR5 
or CXCR4 co-receptors [18, 19], leading to viral fusion with the cell. Once inside, 
the viral proteins and RNA appropriate the cellular machinery to rapidly begin 
producing additional viral particles.    
Like AIDS, genital herpes is also caused by viral infection. This infection is 
caused by HSV, of which there are two types. HSV-2 generally results in genital 
infection with corresponding symptoms; whereas HSV-1 results in oral 
manifestations. More rarely, HSV-1 may infect the genital area. Currently, over 
530 million people worldwide live with HSV-2 infection [20]. This high number of 
infections is attributed to the virus’s ability to infect surface epithelial cells, while 
producing often asymptomatic and latent infections within neuronal cells.  
At its core, each HSV-2 virion is comprised of a capsid that contains 
double stranded DNA [21]. Unlike HIV, the capsid only encodes viral DNA; the 
host’s cellular machinery provides the means for producing additional viral 
particles. The (capsule) is comprised of proteins that form an icosahedral shape, 
surrounded by a lipid bilayer that forms the viral envelope. The lipid bilayer 
contains a variety of surface glycoproteins, five of which are essential for binding 
and entry to host cells: gB, gC, gD, gH, and gL [22, 23].  
 5 
 
While HSV-2 initially infects epithelial cells, post-infection the virus 
anteroretrograde transports to infect neuronal ganglia, providing a reservoir for 
latent infection. Entry into a cell is facilitated by viral glycoproteins gB and gC, 
which non-specifically bind to heparan sulfate [24], a proteoglycan found on the 
surface of host cells. These attachment points induce viral “surfing” to the cell 
surface where gD facilitates receptor-mediated cell binding and internalization 
[21].  After this binding event, gD interacts with a receptor and changes 
confirmation to mediate fusion of the viral envelope with the cell membrane.  The 
conformational change is stabilized by both gB and the gH-gL dimer, which play 
a critical role in viral entry. After entry, the capsule is transferred into the cellular 
nucleus, where viral DNA is transcribed by the cellular machinery.   
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CURRENT HIV AND HSV-2 THERAPEUTICS 
Since isolating HIV in 1983, there has been a monumental effort 
worldwide to prevent, treat, and cure infections. Zidovudine (or azidothymidine, 
AZT), a dideoxynucleoside reverse transcriptase inhibitor (NRTI), was the first 
drug approved by the Food and Drug Administration (FDA) to treat HIV in 1987 
[25]. However, low tolerance, antiviral resistance, and incomplete replication 
inhibition hampered the success of Zidovudine as a stand-alone drug. It is 
currently used in combinational highly active antiretroviral therapy (HAART) 
against HIV. Since the introduction of AZT, dozens of new therapeutics have 
been introduced to combat the AIDs pandemic. 
Today, there are a variety of drugs that have since been developed and 
are widely available to treat HIV. These drugs are categorized based on their 
mechanism of action. Currently there are six types of anti-HIV agents: 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors, co-receptor inhibitors, and integrase inhibitors 
[26]. Nucleotide and nucleoside reverse transcriptase inhibitors (such as AZT) 
are compounds that directly interact with the binding site of the viral reverse 
transcriptase enzyme to inhibit virus replication. Non-nucleotide/nucleoside 
reverse transcriptase inhibitors also work to inhibit reverse transcriptase
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but do not act on the enzyme’s catalytic binding site. Protease inhibitors, similar 
to the previous classes, act against HIV after the virus has entered the cell. PIs 
inhibit HIV protease to prevent the formation of mature viral proteins. In contrast, 
fusion inhibitors act to prevent HIV entry into the cell, by binding to and 
inactivating Env proteins such as gp41. Another method to prevent viral entry is 
the use of co-receptor inhibitors (such as Maraviroc), which prevent gp120 and 
CD4 interaction. Finally, integrase inhibitors, much like reverse transcriptase and 
protease inhibitors, work after viral infection and prevent the virus from 
integrating its genetic material into the host cell DNA. 
This diversity of HIV therapeutics is a result of attempts to combat HIV’s 
highly mutagenic nature. Often, the administration of one compound only 
temporarily hinders HIV infection, and mutation restores HIV replication 
competence, leading to AIDS [27]. With this in mind, Highly Active Antiretroviral 
Therapy (HAART) was introduced. With HAART, a regimen of at least three 
drugs from a minimum of two different classes of drugs is administered to treat 
HIV-1. Typically, several RTIs and at least one PI are administered [28, 29]. The 
vast majority of these medications is taken orally to help increase user 
adherence. Additionally, the different classes of agents help reduce toxicity, 
relative to using drugs of the same class. With the implementation of HAART, 
HIV is suppressed, increasing patient life expectancy by years. 
In contrast to the variety of agents available to treat HIV, only a limited 
number of therapeutics are available to treat HSV-2 [30].  The top three current 
therapeutics are: Acyclovir, Valaciclovir, and Famciclovir. Acyclovir, a guanosine 
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derivative, acts to specifically inhibit viral DNA polymerase activity. The drug was 
one of the earliest therapeutics available to combat HSV-2. However, due to the 
relatively low bioavailability of Acyclovir, the prodrug Valaciclovir was developed. 
Valaciclovir possesses a bioavailability three to five times that of Acyclovir, 
thereby enhancing oral delivery and efficacy [31]. The last drug, Famciclovir, is a 
prodrug of Penciclovir, and possesses a similar mechanism of action as Acyclovir 
but can be administered topically [32]. It is important to note that there are 
currently no FDA-approved therapeutics that prevent or cure HSV.  Furthermore, 
latent infection, combined with frequent asymptomatic and irregular recurrences 
add to the challenge of curing this disease.  
Correspondingly, the challenges in HSV-2 prevention and treatment, 
combined with its high global incidence and propensity for co-infections, 
contribute to the challenges in preventing and curing HIV. In addition to 
increasing the risk of HIV co-infections [33], the asymptomatic nature of HSV 
infection contributes to the lack of awareness of infection, and subsequent co-
infections [34]. Even for asymptomatic cases of HSV-2 infection or latent 
activation, viral loads are present with increased inflammatory and immune cell 
infiltrates. In more severe cases of infection and reactivation, the genital lesions 
caused by HSV-2 significantly increase the likelihood of HIV transmission via 
epithelial tears [35]. With these challenges, multipurpose platforms that prevent 
both HSV-2 and HIV infections are critically needed.  
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ORAL AND TOPICAL PrEP 
Despite the numerous antivirals available to treat HIV and HSV-2, to date 
there are no agents that completely prevent or cure these infections. In terms of 
prevention, pre-exposure prophylaxis (PrEP) has enabled high-risk individuals to 
prevent HIV-1 infection by taking oral medication each day. However, to date, 
only two compounds Tenofovir (TFV) and Emtricitabine (combined with TFV in 
Truvada), are approved for PrEP by the FDA [36].  
Oral PrEP has demonstrated success in preventing HIV in clinical trials 
and is becoming increasingly acknowledged as a successful prevention platform 
[37, 38]. By frequent administration of oral antiretroviral (ARV) compounds, such 
as TFV and Emtricitabine, prevention rates of up to 62% have been achieved in 
clinical trials [39, 40]. Clinical trials such as the Centers for Disease Control and 
Prevention CDC 4243 and CDC 4940, and the International AIDS Vaccine 
Initiative IAVI E001 and IAVI E002, demonstrate the potential effectiveness of 
oral PREP, by reducing HIV infection by up to 75% [41]. However, to achieve 
these levels of protection, frequent administration and strict user adherence are 
critical. This was validated in the VOICE (MTN-003) clinical trial, in which oral 
PrEP (and topical microbicide gels) failed to provide any meaningful protection 
due to a lack of user adherence [42]. In addition to user adherence, additional 
challenges of oral PrEP, based on the administration of ARVs, include renal and 
bone toxicity; associated decreases in condom use; the development of antiviral 
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resistance; and reduction of drug concentration via first pass metabolism [42]. 
Thus new strategies are urgently needed to provide safe, effective, and long-term 
protection against multiple STIs. 
Given the disadvantages of oral PrEP, several topical PrEP strategies 
have been developed that provide localized protection to overcome these 
limitations. Topical PrEP eliminates first-pass hepatic clearance, while providing 
localized doses that result in more efficacious delivery of active agents to the 
local infection site [43]. These localized doses also have the effect of potentially 
reducing drug toxicity. Additionally, by acting at the site of infection, topical PrEP 
improves the ability of active agents to exert their effect upon incoming virus. The 
potential of topical PrEP was demonstrated in the CAPRISA-004 clinical study, 
where a topical gel containing TFV was used to effectively reduce HIV 
transmission by 39% [44].  
While traditionally topical PrEP has been administered in the form of gels, 
topical PrEP delivery vehicles also include films, tablets, and intravaginal rings 
(IVRs). Antiviral gels have the potential to confer adequate protection when 
frequently applied. However in the MTN-003 (Voice) clinical trials, gels containing 
TFV required strict user adherence in administration both prior to and after 
sexual intercourse to maintain effectiveness [43, 45]. The strict dosing needed to 
maintain protection resulted in suboptimal user adherence which led to 
decreased protection against infection. In addition, some users experience 
discomfort or leakiness, which may further reduce user acceptance and 
adherence. Intravaginal films have also demonstrated protection against STIs; 
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however, burst release of incorporated agents is a frequent concern [45]. Indeed, 
the rapid and complete release of the encapsulated agents within hours of 
administration remains a major hurdle of this technology for long-term 
administration [46, 47]. User adherence is another common concern of films, with 
reports of difficulty of administration as well as localized irritation after prolonged 
contact [45, 48]. Vaginal tablets, another topical technology, offer a cost effective 
platform to rapidly release antivirals. However, tablets suffer from the same 
concerns as films, exhibiting transient activity and a lack of long-term release 
[49]. 
In comparison to the previous technologies, intravaginal rings (IVRs) 
provide the gold standard for sustained-release and have demonstrated long-
term protection against STIs for up to 4 months [50, 51]. IVRs have been utilized 
for over a decade, particularly for hormonal contraceptive delivery. The 
translation of IVRs into HIV PrEP has been recently demonstrated in the ASPIRE 
(MTN-020) clinical trial, where HIV infection was reduced by 27% for up to one 
month with Dapivirine encapsulated IVRs [52]. However, concerns remain 
regarding the lack of complete protection provided in clinical trials, and their 
ability to incorporate less stable agents, such as biologics, due to the high 
processing temperatures utilized during the manufacturing process [53]. Lastly, 
user adherence of IVRs remains another major concern. In the ASPIRE trial, 
women most vulnerable to infection (ages 18-21) were less likely to adhere to 
IVR application [52], suggesting that alternative dosage forms may prove 
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beneficial to better address women’s’ preferences and needs for protection; 
improve user adherence; and achieve increased efficacy.   
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ELECTROSPUN FIBERS 
Relative to the existing technologies of gels, films, and IVRs, electrospun 
fibers (EFs) provide a promising alternative for prolonged and localized agent 
delivery, with the potential to protect against multiple STIs. Some of the 
advantages of electrospun fibers include high loading efficiency to increase local 
concentration, enhanced agent stability relative to administration of free agent, 
and tunable sustained-release imparted by material choice. Biodegradable 
polymers, such as poly(lactic-co-glycolic acid (PLGA) and poly(caprolactone) 
(PCL) (Figure 2), are approved by the U.S. Food and Drug Administration (FDA) 
for therapeutic use, indicating their proven biocompatibility and potential for 
translation [54]. Furthermore, due to the variety of polymers available, virtually 
any compound can be incorporated, and delivery durations can be altered to suit 
the specific delivery requirements of a topical delivery vehicle [55, 56].  
Additionally, EFs have the potential to simultaneously deliver co-incorporated 
compounds including biologics such as proteins and oligonucleotides, as well as 
traditional antiviral drugs [57-59]. These attributes make polymeric EFs an 
attractive platform for multipurpose drug delivery against STIs.  
Over the past decade, researchers have begun to incorporate antiviral 
agents into polymeric EFs to prevent HIV infection. One of the first studies to 
utilize electrospun fibers to combat HIV, developed pH-responsive fibers that 
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encapsulated cellulose acetate phthalate (CAP) [60]. The affinity of CAP for the 
HIV surface protein gp120 directly neutralizes HIV. While CAP EFs exhibited 
long-term stability in low pH environments characteristic of the female 
reproductive tract, the EFs quickly degraded with the introduction of semen, to 
release active CAP and neutralize HIV particles. Later research by the same 
group utilized polystyrene and polypropylene fibers to bind to and inhibit HIV [61]. 
In this latter study, fibers were surface-modified with poly(allylamine 
hydrochloride) or dextran sulfate sodium to confer a positive or negative charge 
to the fibers. Both surface-modified EFs inhibited HIV infection with higher 
efficacy than unmodified fibers alone. 
In addition to pH-sensitive and surface-modified fibers, researchers have 
utilized EFs to provide tunable release of one or more incorporated active agents 
for HIV-1 prevention [43-47]. The utilization of polymer blends has enabled fibers 
to be finely tailored to release multiple drugs. Blends of polyethylene oxide (PEO) 
and poly(L-lactic acid) (PLLA) were synthesized to encapsulate the antivirals 
Maraviroc (entry inhibitor) and AZT [62]. By altering ratios of these polymers, 
drug release was tailored to effectively deliver both compounds for up to several 
weeks. In another study, PLGA and PCL fibers were loaded with various 
concentrations of the ARV Tenofovir (TFV) [63]. These fibers demonstrated 
sustained-release of TFV for 30 days as well as efficacy against HIV infection in 
vitro.  
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Figure 2. Chemical structure of PLGA and PCL. Both PLGA and PCL are 
biodegradable polymers widely used in drug delivery research. (A) PLGA is 
comprised of repeating units of glycolic or lactic acid. The addition of lactic acid 
confers greater hydrophobicity to the polymer, resulting in lower degradation rate 
in water. In contrast (B) poly(caprolactone) is highly hydrophobic and does not 
appreciably degrade in water [64]. Lactic acid monomers may be introduced to 
increase the flexibility and hydrophilicity of PCL, resulting in PLCL (poly(DL-
lactide-co-ε-caprolactone)). In our work, this modified derivative of PCL was 
compared with PLGA for the delivery of the ARV drug, Tenofovir disoproxil 
fumarate (TDF). 
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Similarly, but less extensively for HSV-2, PCL matrices were fabricated 
using a heat-based injection molding technique to incorporate increasing 
concentrations of Acyclovir (10, 15, and 20% w/v),  a potent antiviral used for 
treatment against HSV-2 [65].  Encapsulated ACV exhibited release up to 30 
days and retained comparable 50% inhibitory concentration (IC50) to free drug. 
Further work in this field involved the use of TDF-encapsulated IVRs to protect 
against HIV and HSV-2 in vitro and in vivo.  Beyond demonstrating protection 
against HIV and HSV-2 in vitro, these IVRs also prevented HIV infection in 
macaques for up to 4 months (with monthly IVR changes) [50, 51].   
Building upon this previous research, the goal of our work was to develop 
PLGA and PLCL EFs containing three concentrations of the ARV prodrug TDF to 
safely inhibit HIV-1 and HSV-2 infections in vitro (Figure 3). TDF was selected as 
a model ARV, to demonstrate proof-of-concept of our delivery vehicles, due to its 
potent efficacy against both HIV and HSV-2; its increased oral and topical 
lipophilicity and cell permeability; and enhanced IC50 (by 160-fold) relative to its 
prodrug counterpart, TFV [50]. Here we fabricated both PLGA and PLCL EFs to 
evaluate and compare two different biodegradable polymers known to impart 
sustained-release of active agents. In this work we synthesized 3 different 
formulations for each polymer, PLGA and PLCL, and we characterized the 
loading and sustained-release of TDF from EFs. We subsequently assessed the 
efficacy of fiber release eluates against HSV-2 and HIV-1 infection in vitro for up 
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to 4 weeks. We additionally demonstrated the biocompatibility of these EFs in 
vaginal keratinocytes, ectocervical cells, and endocervical cells.  
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Figure 3. Structure of Tenofovir disoproxil fumarate (TDF).  TDF, a prodrug of 
Tenofovir (TVF), was developed to enhance oral bioavailability and efficacy. Both 
TDF and TFV are classified as potent NRTIs; however, TDF has an over 160-fold 
lower IC50 compared to TFV in vivo [50]. Newer derivatives of TFV such as 
Tenofovir alafenamide (TAF) are currently being researched to impart even 
greater efficacy. 
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MATERIALS AND METHODS 
Materials 
Poly(lactic-co-glycolic acid) (PLGA 50:50, 0.55-0.75 dL/g, 31-57k MW) 
and poly(DL-lactide-co-ε-caprolactone) (PLCL 80:20, 0.75 dL/g, 37k MW) were 
both purchased from Lactel Absorbable Polymers (Cupertino, CA). Solvents 1, 1, 
1, 3, 3, 3—hexafluoro-2-propanol (HFIP) and trifluoroethanol (TFE) were 
obtained from Fisher Scientific (Pittsburgh, PA). TDF was purchased as Viread® 
(Tenofovir disoproxil fumarate, Gilead Sciences Inc., Foster City, CA) tablets 
from the University of Louisville Pharmacy. Other chemicals, including dimethyl 
sulfoxide (DMSO) and Thiazolyl Blue Tetrazolium Bromide (MTT) were 
purchased from Sigma Aldrich (St Louis, MO). Fetal bovine serum (FBS), 
antibiotics (penicillin/streptomycin and gentamicin), Minimum Essential Medium 
(MEM), Keratinocyte Serum-free Medium (KSFM), and Dulbecco’s Modified 
Eagle Medium (DMEM) were purchased from VWR and Thermofisher. Simulated 
vaginal fluid (SVF) was prepared in house using a previously established 
protocol  [66].  
 
Cell Lines and Virus 
TZM-bl cells were obtained from the NIH AIDS Research and Reference 
Reagent Program (ARRRP). These cells are a genetically engineered HeLa cell 
clone that expresses CD4, CXCR4, and CCR5 and contain Tat-responsive 
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reporter genes for firefly luciferase (Luc) and Escherichia coli β-galactosidase 
under regulatory control of an HIV-1 long terminal repeat [67, 68]. TZM-bl cells 
were maintained in Gibco Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) containing 10% heat-inactivated FBS, 25 nM HEPES, and 50 µg/mL 
gentamicin, in a vented T-75 culture flask. Env-pseudotype HIV was kindly 
provided by Dr. Nobuyuki Matoba from the University of Louisville. To conduct 
HSV-2 plaque assays, African green monkey kidney (Vero E6) cells and HSV-2 
(4674) were kindly provided by Dr. Kenneth Palmer from the University of 
Louisville. Cells were maintained in MEM supplemented with 10% FBS, penicillin 
(100 µg/mL), and streptomycin (100 µg/mL). 
To assess cytotoxicity, Endocervical, End1/E6E7 (End1); ectocervical, 
Ect1/E6E7 (Ect1); and vaginal keratinocyte, VK2/E6E7 (VK2) cell lines were 
used (courtesy of Dr. Kenneth Palmer). These cell lines were selected because 
they are representative of the cell types in the female reproductive tract that 
would be exposed to the topical EFs. End1, Ect1, and VK2 cells were maintained 
in KSFM supplemented with bovine pituitary extract (50 µg/mL), epidermal 
growth factor (0.1 ng/mL), penicillin (100 µg/mL), and streptomycin (100 μg/mL). 
The media was further supplemented with calcium chloride (CaCl2) to a final 
concentration of 0.4 mM. During cell trypsinization for plating and cell count, cells 
were neutralized using DMEM/F12 (Gibco) with 10% FBS, and 1% 
Penicillin/Streptomycin.   
 
Synthesis of Electrospun Fibers 
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PLGA and PLCL EFs were prepared with different solvents and TDF 
concentrations spanning (1-20% wt drug/wt polymer (w/w)). Blank fibers 
containing no TDF were prepared as negative controls. For blank EFs, 15-20% 
PLGA w/w and 12-20% PLCL w/w were dissolved in either 3 mL TFE or HFIP 
solvent overnight while shaking at 37 °C. The following day, 2 mL of PLGA or 
PLCL solution was aspirated into, and electrospun from a 3 mL plastic syringe on 
a custom built device housed in an air-filtered Plexiglas chamber. All formulations 
were electrospun with a flow rate of 2.0 mL/hr and an applied voltage of 20 kV. 
EFs were collected on a rotating 4 mm outer-diameter stainless steel mandrel, 
located 20 cm from the blunt needle tip. Sample flow rate was monitored by an 
infusion pump (Fisher Scientific, Pittsburgh, PA) and the voltage was applied 
using a high voltage power supply (Spellman CZE 1000R). For fibers 
incorporating TDF, 1, 10, or 20% w/w TDF was dissolved in 1.2 mL solvent 
overnight. The next day the TDF solution was added to 1.8 mL polymer solution 
prior to electrospinning. After electrospinning, fibers were removed from the 
mandrel and dried overnight in a desiccator cabinet.  
 
Electrospun Fiber Size and Morphology 
The impact of various parameters including: solvent choice, polymer 
composition, and TDF concentration on fiber size and morphology were 
evaluated using scanning electron microscopy (SEM). Desiccated EFs were 
placed on carbon tape, sputter coated with gold, and imaged using SEM (Supra 
35 SEM Zeiss). SEM images were acquired at magnifications ranging from 
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1,000-5,000x to enable clear visualization of the fiber microstructure. The 
average fiber diameter was determined by analyzing SEM images in NIH 
ImageJ, and drawing line elements across a minimum of 50 fibers per image.  
Statistical significance between fiber diameters was determined using the Tukey 
post hoc t-test (p < 0.05). 
 
Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled 
Release 
Incorporated TDF was quantified by dissolving 5 mg of PLGA and PLCL 
EFs in 1 mL of (1 M) NaOH overnight. TDF in the supernatant was measured 
using UV absorption spectroscopy at 260 nm (Synergy HT Biotek) in UV 
transparent 96-well plates. Quantification was performed using a TDF standard 
diluted in NaOH, with blank fibers as background correction. TDF values 
determined from absorbance measurements were compared with the quantity of 
TDF added prior to electrospinning to obtain percent encapsulation efficiency 
(EE), where EE = [(Mass of TDF Incorporated)/(Mass of TDF Initially Added)] x 
100. Unless otherwise noted, all samples were analyzed in triplicate. 
Controlled release experiments were performed to assess the release of 
TDF from EFs. Triplicate 10 mg fiber pieces were cut and suspended in 1 mL of 
simulated vaginal fluid (SVF) to represent intravaginal conditions in vitro. 
Samples were incubated at 37 °C and constantly shaken. The complete volume 
of SVF was removed and replaced with fresh SVF at time points: 1, 2, 4, 6, 24, 
48, 72 hr, and 1, 2, 3, and 4 wk. Statistical significance of both loading and 
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release profiles between fiber formulations were determined by one-way ANOVA 
with the Bonferroni post hoc t-test (p < 0.05) 
 
In Vitro Efficacy of PLGA and PLCL Fibers against HIV-1 infection 
HIV pseudovirus assays were used to assess the efficacy of TDF released 
from EFs against HIV infection in vitro. TZM-bl cells were infected with Env-
pseudotype HIV, kindly provided by both Dr. Nobuyuki Matoba (University of 
Louisville) and the NIH AIDS Research and Reference Reagent Program 
(ARRRP). To produce and propagate HIV Env-pseudovirus, HEK293T/17 cells 
were transfected with two plasmids, one containing an Env-defective HIV 
genome and a plasmid solely expressing Env. Transfection was facilitated with 
the use of FuGENE (Promega). HEK293T cells were allowed to incubate for 48 
hr, after which viral particles were collected and titered using the 50% Tissue 
Culture Infectious Doses assay (TCID50). Viral particles were stored at -80 °C 
until use [69]. 
To determine the in vitro efficacy of PLGA and PLCL TDF EFs against 
Env-pseudotype HIV infection, TZM-bl cells were seeded in 96-well plates at 
100,000 cells/well in 100 µL of DMEM. Fifty microliters of fiber eluate media 
(DMEM 10% FBS) collected from time points: 1 and 24 hr; week 1; week 2 
(release from days 7-14), week 3 (release from days 14-21), and week 4 (release 
from days 21-28) were diluted by a maximum of 5 orders of magnitude from 
collected eluate (1:100,000 maximum dilution). Eluate dilutions were added to 
cells in triplicate, and 50 µL of diluted virus stock (1:8) was subsequently added 
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to each well. The administered virus dose resulted in relative luminescence units 
(RLU) of at least twenty times that of background (untreated/uninfected cells), 
yielding an average maximum of 100,000 RLUs in our experiments. Three 
controls were used in the experiment: untreated/uninfected cells, 
untreated/infected cells, and blank fiber eluate-treated/infected cells. For wells 
containing untreated/uninfected and untreated/infected cell controls, 100 µL 
DMEM was added to the wells; for infected cells with blank fiber eluate, 50 µL 
DMEM was added to 50 µL blank fiber eluate. After infection, plates were 
incubated 48 hr at 37 °C. After incubation, 100 µL of media was removed from 
each well and replaced with 100 µL of Bright Glo Reagent (Promega). Cells were 
incubated at room temperature for another 5 minutes and the luminescence of 
each well was read. The amount of virus inhibition was determined by 
normalizing the RLUs of infected treated cells to untreated/infected cells. 
Additionally, all RLU values were corrected by subtracting the RLU of 
untreated/uninfected cells. IC50 values were determined using GraphPad 6.0 
sigmoidal regression analysis. Unless otherwise noted, all experiments were run 
with three or more replicates per treatment group. Statistical significance 
between the IC50s was determined using one-way ANOVA with the Bonferroni 
post hoc t-test. 
 
In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection 
HSV-2 plaque assays were conducted to test the efficacy of TDF EFs 
against HSV-2 infection in vitro. Fibers were incubated in 10 mL complete plating 
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media (1% FBS MEM) for 1 and 24 hr. Additional fiber eluates were collected at 
week 1; week 2 (release from days 7-14); week 3 (release from days 14-21); and 
week 4 (release from days 21-28) to assess the ability of PLGA and PLCL TDF 
EFs to provide prolonged delivery and corresponding HSV-2 protection. The 
antiviral activity of PLGA and PLCL TDF EF eluates was determined using HSV-
2 (4674) plaque assays in Vero E6 cells. Vero E6 cells were seeded at 600,000 
cells/well and grown to near confluence for 24 hr in a 6-well flat bottom plate. 
After 24 hr, the media was removed and cells were simultaneously administered 
2 mL of fiber eluate serial dilutions from the above collected time points and 
3,000 PFU of HSV-2 per well. Free TDF was used as a positive control for HSV-2 
inhibition, in parallel with untreated/uninfected cells; whereas untreated/infected 
cells were used as a positive control of cell infection and death. After 48 hr, cells 
were fixed with methanol for 10 min, stained with 0.1% crystal violet for 30 min, 
and washed with DI water. Plaques were counted, and plaque numbers from 
experimental groups were normalized relative to the number of plaques in 
untreated/infected cells (~280-300 plaques). Samples were analyzed in triplicate, 
and GraphPad was used to determine the IC50 values of the TDF EF 
formulations. Statistical analysis was performed by comparing the average 
percent inhibition of HSV-2 using one-way ANOVA with the Bonferroni post hoc t-
test.  
 
In Vitro Cytotoxicity of PLGA and PLCL Fibers 
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Vaginal epithelial (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical 
(End1/E6E7) cells were incubated with TDF EFs in KSFM to assess the in vitro 
biocompatibility of TDF fibers. Cells were plated at a density of 300,000 cells/well 
in 12-well plates and incubated in triplicate with 1 mg fiber pieces placed in 
transwell inserts (1 mg/mL final concentration). No treatment (media alone) and 
10% DMSO were used as positive and negative controls of cell viability, 
respectively. After 24, 48, and 72 hr incubation, 10 mL of MTT reagent was 
added to the cells, cells were lysed, and absorbance was read at 570 nm the 
following day. PLGA and PLCL EF-treated cell absorbance values were 
normalized to untreated cell absorbance to obtain percent viability.  
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RESULTS 
Electrospun Fiber Size and Morphology 
 Fiber morphology was evaluated using SEM, and ImageJ software was 
used to assess fiber diameters. Figure 4 shows blank PLGA and PLCL fibers 
fabricated using either HFIP or TFE solvent. For fibers electrospun in HFIP, 15% 
w/w PLGA or 12% w/w PLCL provided well-defined fiber morphologies. However 
with TFE, both polymers required an increase in concentration to 20% (w/w) to 
produce well-delineated microstructures. The average diameters were 2.0 ± 0.8 
and 1.7 ± 0.4 µm for 15% PLGA and 12% PLCL fibers made with HFIP, and 1.9 
± 0.9 and 1.9 ± 0.8 µm for 20% PLGA and 20% PLCL fibers made with TFE. 
Once well-delineated fibers were established, the effect of TDF incorporation on 
PLGA and PLCL EF morphologies electrospun with HFIP was evaluated (Figure 
5).   
 The morphologies and diameters of TDF EF formulations are shown in 
Figures 5 and 6, respectively. Prior to TDF incorporation, the average diameters 
of all blank fiber formulations were similar, ranging from 1.7 to 2.0 µm, with no 
statistical significance observed between formulations (Figure 6A). In 
comparison, fibers incorporating TDF showed a random distribution of fiber 
diameters for PLGA; whereas for PLCL, a decreased trend in fiber diameter was 
observed. The average fiber diameters for HFIP 15% PLGA 1%, 10%, and 20% 
TDF were 1.1 ± 0.3, 0.7 ± 0.2, and 1.1 ± 0.4 µm. For HFIP 12% 
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PLCL 1%, 10%, 20% TDF fibers, the resulting fiber diameters were 1.1 ± 0.5, 0.9 
± 0.3, 0.7 ± 0.2 µm, with PLCL fibers demonstrating a decrease in fiber diameter 
between blank (no TDF) and TDF-incorporated formulations. Additionally, TDF 
incorporated fibers electrospun with TFE solvent, displayed a similar decrease in 
diameters to 1.2 ± 0.4 µm and 0.6 ± 0.2 µm, for PLGA and PLCL respectively. All 
TDF fiber diameters had statistically different diameters relative to blank PLGA 
and PLCL EFs. However, no statistical significance was observed between the 1, 
10, and 20% TDF fiber formulations as a function of TDF incorporation. 
Additionally, there was no statistical difference in diameter between TDF 
incorporated PLGA and PLCL fibers. Thus any addition of TDF resulted in 
decreased fiber diameter relative to blank fibers; whereas additional TDF 
incorporation had no significant effect on fiber diameter. 
 
 
 
 
 29 
 
 
 
Figure 4. SEM images of blank PLGA and PLCL fibers electrospun using 
different solvents. (A) 15% w/w PLGA in HFIP; (B) 20% w/w PLGA in TFE; (C) 
12% w/w PLCL in HFIP; and (D) 20% w/w PLCL in TFE. Scale bars represent 10 
µm.  
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Figure 5. SEM images of PLGA and PLCL fibers prepared with increasing 
concentrations of TDF (1%, 10%, 20% w/w), using HFIP as solvent. (A) Blank 
PLGA, (B) 1% TDF, (C) 10% TDF, and (D) 20% TDF PLGA fibers; (E) Blank 
PLCL, (F) 1% TDF, (G) 10% TDF, and (H) 20% TDF PLCL fibers. Scale bars 
represent 10 µm.  
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Figure 6. Average diameters of electrospun fibers measured from SEM images, 
using ImageJ. (A) Diameters of blank PLGA and PLCL fibers electrospun with 
either HFIP or TFE solvents. Diameters ranged from 1.7 to 2.0 m. No statistical 
significance was observed between fiber diameters prepared with either HFIP or 
TFE. (B) Diameters of TDF-incorporated EFs were significantly smaller than 
blank fiber counterparts, ranging from 0.7 to 1.2 m (TFE data not shown).  While 
the PLGA TDF fiber diameters seemed randomly distributed, PLCL TDF fibers 
demonstrated a trend of decreased diameter with increasing TDF concentration. 
While statistical significance was observed between blank fibers and all TDF fiber 
formulations, no statistical difference in diameters was observed between the 
TDF EF formulations. 
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Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled 
Release 
 To determine the loading of TDF in PLGA and PLCL EFs, fibers and 
unincorporated TDF were weighed and dissolved overnight in (1M) NaOH.  Serial 
dilutions of TDF in NaOH were used to create a standard curve (Figure 7).  The 
linear range of the standard curved extended from 1 mg/mL to 488 ng/mL of 
TDF. All concentrations of TDF (1, 10, and 20% w/w) fibers and standards were 
measured via absorbance at 260 nm. Table 1 summarizes the total loading (µg 
TDF/mg fiber) and encapsulation efficiency (EE) achieved for the various fiber 
formulations. Overall, we observed that fibers electrospun with HFIP resulted in 
high EEs spanning 43-75%. The 10% TDF PLGA and PLCL fibers electrospun 
with HFIP solvent were compared to 10% TDF PLGA and PLCL fibers 
electrospun with TFE, to assess the loading difference based on electrospinning 
solvent choice. Whereas the 10% TDF PLGA and PLCL EFs electrospun with 
HFIP showed a high encapsulation efficiency of 69% for each formulation, the 
TFE EFs incorporated only 41-44% TDF. Within the HFIP electrospun fibers, the 
1% TDF PLGA and PLCL fibers incorporated less than half of the added TDF, 
showing the least incorporation of all formulations, while the 10% TDF fibers 
demonstrated consistently high EE around 69%. The 20% TDF fibers showed 
some variability in EE based on polymer type, with PLGA incorporating 56% TDF 
and PLCL incorporating 76%. Since the electrospun fibers made with HFIP 
showed 30% higher encapsulation than TFE fibers (for the 10% formulation), in 
addition to the high polymer concentration required to fabricate well-delineated 
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fibers with TFE (20% for PLGA and PLCL vs. 12 and 15% for PLGA and PLCL, 
respectively), HFIP was selected to electrospin subsequent formulations.   
 After determining the PLGA and PLCL fiber loading, we assessed the 
release of TDF from PLGA and PLCL EFs in SVF for up to 4 weeks. Standard 
solutions of TDF in SVF were prepared to assess TDF release in SVF eluates 
(Figure 8).  Measuring absorbance at 260 nm, the standard curve ranged from 
488 ng/mL to 1mg/mL of TDF.  Figure 9 demonstrates increased TDF release 
per mass of fiber, with increased incorporation of TDF for both PLGA and PLCL. 
All fiber formulations experienced a burst release spanning 0-60% for each 
formulation after 48 hr of release. Based on total percent loading, the 10% and 
20% PLCL EFs showed greater burst release of 3% and 21%, respectively at 1 
hr, compared to the 10% and 20% PLGA fibers (Figure 9B). However, after 24 hr 
incubation, both 10% and 20% PLGA and PLCL EFs released nearly equivalent 
amounts of TDF per total loading. Similarly, cumulative release of TDF per mass 
of fiber showed that 10% and 20% PLCL fibers released more TDF (35 and 39 
µg/mg) than corresponding PLGA fibers at 1 hr. After 24 hours, the differences in 
TDF released between PLCL and PLGA fibers decreased to 29 and 7 µg/mg for 
the 10% and 20% formulations, respectively.  
 For prolonged release after 4 weeks, PLGA fibers exhibited higher 
cumulative release of incorporated TDF per mass of fiber, compared to PLCL 
fibers, with the exception of the 10% TDF EFs (Figure 9A). On a percent loading 
basis however, PLGA fibers consistently released more TDF than PLCL fibers for 
the 1%, 10%, and 20% TDF formulations. PLGA fibers released 25, 70, and 86% 
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of their cargo; whereas PLCL fibers released, 52, and 73% of their cargo for the 
10% and 20% formulations after 4 wk. TDF release was not detected from the 
1% PLCL formation. Furthermore, we observed an increase in release at 21 days 
from all PLGA fibers, which can be attributed to polymer matrix degradation 
under acidic conditions.  From these experiments we observed that PLGA fibers 
have the potential for increased sustained-release over a 4 week period based 
on percent loading, relative to PLCL fibers which seemed to plateau after initial 
burst release. However, on a mass-by-mass basis, PLGA fibers were only 
slightly improved for release relative to PLCL fibers, with the exception of the 
10% TDF PLGA formulation. 
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Table 1.  
Quantification of TDF fiber loading and encapsulation efficiency.  
 
PLGA and PLCL fibers electrospun with HFIP demonstrated higher loading and 
encapsulation efficiencies, relative to PLGA and PLCL fibers electrospun with 
TFE. Furthermore, linear increases in encapsulation efficiency were observed 
based on the amount of TDF added to PLGA and PLCL formulations. 
 
 
 
 
 
 
 
 
 
 
Loading TDF/Fiber       
(µg/mg)
Encapsulation Efficiency      
(%)
1% TDF 10 ± 0.3 45 ± 1.6
10% TDF 88 ± 3.9 69 ± 2.5
20% TDF 162 ± 1.8 56 ± 0.6
1% TDF 7 ±0.1 43 ± 0.6
10% TDF 87 ± 1.8 69 ± 1.4
20% TDF 171 ± 3.3 75 ± 1.4
91 ± 6.5 44 ± 2.5
98 ± 10.8 41 ± 3.7TFE 20% PLCL 10% TDF
Fiber Formulation
HFIP 15% PLGA
HFIP 12% PLCL
TFE 20% PLGA 10% TDF
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Figure 7. The standard curve used to quantify TDF loading and encapsulation 
efficiency.  Fibers and TDF standard were dissolved overnight in (1M) NaOH.  
Samples and TDF standard absorbance were read at 260 nm. The initial stock 
concentration of free TDF was 1000 µg/mL. Serial dilutions of 1:2 were 
performed in UV 96-well plates.  The limit of detection determined from this 
standard curve was 0.488 µg/mL TDF, and the linear range extended from 0.488 
to 1000 μg/mL TDF. 
 
 
 
 
 
 
 37 
 
 
Figure 8. The standard curve used to quantify TDF sustained-release. The free 
TDF standard was diluted in simulated vaginal fluid (SVF) to quantify fiber 
release eluates in SVF.  Samples and TDF standard absorbance were read at 
260 nm. The initial stock concentration of free TDF was 2000 µg/mL; however, 
the linear range of this standard curve extended from 0.488 to 1000 μg/mL TDF. 
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Figure 9. Sustained-release profiles of 1, 10, and 20% TDF PLGA and PLCL 
fibers in SVF.  (A) Cumulative release of TDF per milligram of fiber (µg TDF/mg 
fiber) over one month.  (B) Cumulative release of TDF as percent total loading 
(%) over one month. While PLCL fibers showed a higher burst release after 1 hr, 
overall PLGA fibers exhibited greater sustained-release over the course of 4 wk, 
relative to PLCL fibers.  In agreement with our previous work release of TDF from 
PLGA fibers in the acidic environment of SVF increased at 21 days [70].   
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In Vitro Efficacy of PLGA and PLCL Fibers against HIV-1 infection 
Short-Term Efficacy  
 To assess the antiviral activity of TDF PLGA and PLCL fibers, HIV 
inhibition assays were performed using fiber eluates collected at different 
controlled-release time points. Both short- and long-term release samples were 
collected to assess efficacy after different time points. For short-term (1 and 24 
hr) assessment of antiviral activity, 10 mg fibers were incubated in 1 mL DMEM 
for 1 or 24 hr. A histogram of the HIV inhibition after administration of the 1 hr 
(Figure 10A) or 24 hr fiber release eluates (Figure 10B) is shown in Figure 10 
and the corresponding IC50s are shown in Table 2. All EFs with 10 or 20% TDF 
completely inhibited viral infection in TZM-bl cells down to a 1:100 dilution.  
  For dilutions of 1 and 24 hr eluates exceeding 1:100, viral inhibition was 
more pronounced after administration of the 24 hr eluates, relative to 1 hr 
eluates. The increased efficacy observed with 24 hr eluates can be attributed to 
the higher amount of TDF released within 24 hr. For both time points, the PLCL 
fibers seemed to impart greater protection against in vitro infection. This was 
quantified by calculating the IC50 values for all PLGA and PLCL TDF fibers 
(Table 2).  
 Overall, the antiviral activities of these eluate dilutions demonstrate that 
the amount of TDF in the fiber correlates well with increased viral inhibition. For 
the 1% TDF PLGA and PLCL fibers, 1 hr undiluted eluates decreased infection to  
27% and 10%, relative to untreated/infected controls at 100% infection. However, 
subsequent dilutions of the 1% TDF 1 hr eluates yielded decreased protection 
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against HIV-1 infection. In contrast, after 24 hr release, the 1% TDF PLGA and 
PLCL fibers completely inhibited virus infection, with subsequent decreases in 
virus inhibition corresponding with increased eluate dilution. Full infection 
resulted after administration of the 1% PLGA and PLCL fibers at a dilution of 
1:10, and 1:1000, respectively for the 1 hr eluates; and 1:1000 and 1:100 for the 
PLGA and PLCL 24 hr eluates. 
 For the 10% TDF formulations, both PLGA and PLCL fibers exhibited 
complete protection against HIV down to 1:100 and 1:1000 eluate dilutions, 
respectively after 1 hr. After administration of the 24 hr eluates, complete 
protection was observed even after a 1:1000 dilution of each formulation. 
Subsequent dilutions of PLGA eluates for 1 hr and 24 hr time points exhibited an 
increase in infectivity (decrease in prevention) to 31% and 13% for 1:1000, and 
complete infectivity for 1:10,000 dilutions, respectively. For PLCL, complete 
protection was achieved with the 1:1000 eluate dilutions at both 1 and 24 hr time 
points. Additionally, these fibers showed efficacy even at eluate dilutions of 
1:10,000, with 48% and 69% infectivity at 1 and 24 hr. The corresponding IC50s 
for 10% TDF PLGA and PLCL EFs were 33 and 49 ng/mL after 1 hr, and 55 and 
43 ng/mL after 24 hr (Table 2). 
 As expected, the 20% TDF fibers exhibited the highest efficacy against 
HIV infection per mass of fiber tested. Similar to the 10% TDF PLGA and PLCL 
EFs, 20% TDF fibers completely inhibited infection after a 1:1000 dilution, and 
exhibited partial efficacy (58-100%) between 1:10,000 and 1:100,000 dilutions. 
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The corresponding IC50s for 20% TDF PLGA and PLCL EFs were 34 and 29 
ng/mL after 1 hr release, and 63 and 30 ng/mL after 24 hr release (Table 2). 
 Overall, the IC50s of TDF PLCL fibers were lower (more efficacious) than 
the IC50s of PLGA TDF fibers for the 10% and 20% formulations at 1 and 24 hr. 
The only exception was the 1 hr 10% TDF PLGA EF release eluate, which 
demonstrated higher efficacy relative to PLCL EFs. In addition, the IC50s of all 
TDF fiber eluates were compared to the IC50s of free TDF exposed to media for 
similar durations. As shown in Table 2, all fibers demonstrated equivalent or 
lower IC50s relative to free TDF (90 and 65 ng/mL at 1 and 24 hr respectively). 
Although increased TDF incorporation correlated to higher protection against HIV 
infection, after accounting for TDF concentration, all TDF fibers proved similarly 
efficacious. There was no statistical difference between the IC50s of the different 
polymer formulations at 1 and 24 hr time points of release. Additionally, no 
statistical significance was found between the same fiber formulations at different 
time points. Finally, there was no statistically significant difference between fiber 
and free TDF IC50s, suggesting that either could be used to provide short-term 
protection for 1 or 24 hr.   
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Figure 10. Results from in vitro HIV-1 infection assays. PLGA and PLCL fiber 
eluates inhibit HIV infection after 1 and 24 hr (A and B), and 1 and 2 wk of 
release (C). Dilutions of release eluate from 10 mg/mL fiber concentrations at 
different time points were normalized to untreated/infected cell control RLUs to 
assess percent HIV inhibition in vitro. Figures show the percent of cells infected, 
after incubation with: (A) 1 hr release eluate; (B) 24 hr release eluate; and (C) 1 
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and 2 wk release eluate from 20% TDF PLGA and PLCL fibers only, compared to 
(D) blank fiber eluates at each time point, and (E) free TDF (200 µg/mL) eluate 
for 1 and 2 wk. After 3 and 4 wk incubation, minimal protection against HIV-1 was 
shown for all fiber eluates (F).  The 20% TDF PLGA fibers eluates showed no 
protection even for undiluted eluates.  In contrast, undiluted 20% TDF PLCL 
eluates inhibited infection by 55%; however, no protection was demonstrated at 
1:10 dilution.   
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Table 2. 
PLGA and PLCL fiber IC50s (against HIV-1) after administration of the 1 and 24 
hr eluates.  
 
The IC50s of TDF fiber eluate are similar or less than free TDF (91 and 65 
ng/mL). However, no statistical significance between formulations at the same 
time point, within the same formulation at different time points, or between 
formulations and free TDF at the same time point were observed (p > 0.05). 
Confidence intervals of IC50s are shown in parentheses.  
 
 
 
 
 
 
 
 
 
Fiber Formulation
IC50 at 1 Hr                
(ng/mL)
IC50 at 24 Hr             
(ng/mL)
PLGA 10% TDF 33 (27 to 40) 55 (46 to 67)
PLGA 20% TDF 34 (27 to 51) 63 (43 to 89)
PLCL 10% TDF 49 (39 to 60) 43 (20 to 90)
PLCL 20% TDF 29 (19 to 46) 30 (18 to 45)
Free TDF 91 (82 to 100) 65 (18 to 120)
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Long-Term Efficacy  
 To assess the long-term efficacy of the fibers against HIV infection in vitro, 
eluates were collected from 10 mg of 20% TDF PLGA and PLCL fibers after 
incubation in 1 mL DMEM for 1, 2, 3, and 4 wk. Twenty percent TDF fibers were 
selected due to their greater efficacy and applicability to future dosing potential in 
vivo. A histogram of HIV inhibition after administration of the 1 and 2 wk fiber 
release eluates is shown in Figure 10C and the corresponding IC50s are 
quantified in Table 3. After 1 and 2 wk, both PLGA and PLCL EFs completely 
inhibited HIV infection with no dilution. However, only the 1 wk eluates 
completely inhibited HIV infection, even after a 1:100 dilution. Two week eluates 
demonstrated weaker activity, showing only marginal protection (14% and 27%) 
at 1:10 dilutions of PLGA and PLCL fiber eluates, respectively. The 
corresponding IC50s were 60 and 350 ng/mL for 1 wk PLGA and PLCL eluates 
and 18,530 and 2900 ng/mL (18.5 and 2.9 μg/mL) for 2 wk PLGA and PLCL 
eluates. Free TDF controls showed a similar decrease in inhibition, relative to 
their IC50s after 1 and 24 hr exposure to media (91 and 65 ng/mL), to 34,050 
and 37,250 ng/mL (34 and 37.2 μg/mL) at 1 and 2 wk, suggesting the 
degradation of free TDF after prolonged exposure to media (Figure 10E).  
Undiluted samples from weeks 3 and 4 showed minimal protection against HIV at 
the doses tested (Figure 10F). 
 Although PLGA showed higher efficacy (60 ng/mL), relative to PLCL (350 
ng/mL) for 1 wk eluates, the IC50s between PLGA and PLCL were not 
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statistically significant. However, the IC50s of both PLGA and PLCL fibers were 
statistically significant compared to free TDF (p < 0.05). Furthermore, all IC50s of 
the 1 wk eluates were statistically significant (p < 0.05) relative to the 1 hr, 24 hr, 
and 2 wk time points. For 2 wk eluates, all samples exhibited IC50s that were 
statistically different from each other. While TDF PLGA EFs demonstrated a 
marked increase in IC50 after 2 wk compared to PLCL with IC50s of 18,530 
ng/mL and 2,900 ng/mL (18.5 and 2.9 ng/mL) respectively, both PLGA and PLCL 
EFs proved more efficacious at 1 and 2 wk than administration of free TDF.  
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Table 3.  
PLGA and PLCL fiber IC50s (against HIV-1) after administration of long-term 1 
and 2 wk release eluates. 
  
As exposure time to media increased, the efficacy of TDF fibers decreased.  
However, both PLGA and PLCL fiber eluates were more efficacious than free 
TDF after 1 and 2 wk exposure to media.  Confidence intervals of IC50s are 
shown in parentheses. 
 
 
 
 
 
 
 
 
 
 
Fiber Formulation
IC50 at 1 or 2 Wk            
(ng/mL)
PLGA 1 Wk 60 (28 to 126)
PLGA 2 Wk 18530 (6609 to 51000)
PLCL 1 Wk 350 (260 to 460)
PLCL 2 Wk 2900 (1600 to 5300)
TDF 1 Wk 34050 (29710 to 39750)
TDF 2 Wk 37250 (33790 to 41070)
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In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection 
 To evaluate the potential of these fibers to inhibit HSV-2 infection, the 
antiviral efficacy of TDF EFs was also assessed in HSV-2 plaque assays. Due to 
higher concentrations required for future in vivo work, only 20% TDF PLGA and 
PLCL fibers were evaluated. Similar to the HIV infection assay, eluate from 5 
mg/mL fibers at 1 and 24 hr was tested and shown to completely inhibit viral 
plaque formation. Figure 11 illustrates the results of serial dilutions (1:1.5) of 1 
and 24 hr eluates. Both PLGA and PLCL fiber eluates completely inhibited HSV-
2 infection, and exhibited decreased protection with increased dilution. Eluates 
from 24 hr showed greater efficacy against HSV-2 infection due to the increased 
amount of released TDF. 
 The IC50s of incorporated TDF from both PLGA and PLCL fibers were 
assessed using these dilutions. These results (Figure 12 and Table 4) show that 
the IC50s of PLGA and PLCL 1 and 24 hr eluates were comparable to the free 
TDF IC50 of 16 µg/mL. While the plaque assays showed enhanced protection 
across dilutions provided by PLGA EFs after 1 and 24 hr, after accounting for 
fiber loading, there was no significant difference in efficacy between most of the 
fiber IC50s and free TDF. The only statistical differences were found with PLGA 
1 and 24 hr eluates exhibiting higher efficacy against HSV-2 relative to PLCL 1 hr 
eluates.   
 Fiber eluates were also collected to assess HSV-2 protection after 1, 2, 
and 3 wk. For these time points and fiber concentration (5 mg/mL) tested, no 
 49 
 
virus inhibition was observed (data not shown). Similarly, free TDF controls 
showed a dramatic decrease in efficacy against HSV-2 infection by 1 wk.  
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Figure 11. Results from in vitro HSV-2 infection assays. Plaque assays were 
conducted to assess the efficacy of 20% TDF PLGA and PLCL fiber eluates (5 
mg/mL) against HSV-2 infection in vitro. Plaques were counted and normalized 
to untreated/uninfected samples. Results demonstrate HSV-2 efficacy attained 
with: (A) 1 hr and (B) 24 hr fiber eluate dilutions. TDF fibers were effective 
against HSV-2 infection at 1 and 24 hr; however, at the concentration tested, 
proved ineffective for all other eluate time points (data not shown).  
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Figure 12. IC50 curve of HSV-2 plaque assay inhibition. The log of TDF fiber 
eluate concentration is plotted against plaque numbers that have been 
normalized to untreated/infected samples. Both PLGA and PLCL TDF fiber 
eluates from 1 and 24 hr show similar IC50s to free TDF (~16 µg/mL).  
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Table 4.  
PLGA and PLCL fiber IC50s (against HSV-2) after administration of the 1 and 24 
hr eluates 
  
Plaque assays were performed to assess the antiviral activity of 20% TDF fiber 
eluates against HSV-2 infection. Fiber eluates from 1 and 24 hr showed similar 
activity, relative to free TDF. However, 1, 2, 3, and 4 wk eluates were ineffective 
with the dose administered, against HSV-2 infection (data not shown). 
Confidence intervals of IC50s are shown in parentheses. 
 
 
 
 
Fiber Formulation IC50 (µg/mL)
PLGA 20% TDF (1 hr) 14.78 (13.25 to 16.49)
PLGA 20% TDF (24 hr) 14.95 (13.55 to 16.55)
PLCL 20% TDF ( 1 hr) 14.93 (14.42 to 15.47)
PLCL 20% TDF (24 hr) 15.35 (13.86 to 16.99)
Free TDF 15.73 (14.0 to 17.68)
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Figure 13. Representative pictures from HSV-2 plaque assays using undiluted 
fiber eluates. Undiluted eluates from the 24 hr release of 5 mg/mL fibers were 
incubated with Vero cells and HSV-2 for 48 hr. Eluates from fibers with 
increasing percent TDF exhibited greater protection against HSV-2 infection. 
20% TDF PLGA and PLCL fibers completely inhibited HSV-2 plaque formation. 
Control wells with untreated/uninfected cells and TDF-treated (400 μg/mL TDF-
infected cells similarly showed no plaque formation. Conversely, the positive 
control of HSV-2 infection − administration of eluates from blank fibers − showed 
the highest number of plaques. 
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In Vitro Cytotoxicity of PLGA and PLCL Fibers 
 Fiber cytotoxicity was assessed in VK2, Ect1, and End1 cells, using the 
MTT assay.  As seen in Figure 14, high cell viability was maintained after 
administration of TDF fibers for 24, 48, and 72 hr. All cells demonstrated greater 
than 93, 91, and 96% cell viability at 24, 48, and 72 hr respectively, for all 
formulations tested. Ten percent DMSO was used as a positive control for cell 
death.  
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Figure 14. Cytotoxicity assessed via MTT assay. Vaginal epithelial cell lines: (A) 
Ect1 E6/E7, (B) VK2 E6/E7, (C) and End1 E6/E7, were incubated with blank or 
TDF PLGA or PLCL fibers (10 mg/mL) in 12-well plates. Viability was assessed 
at 24, 48, and 72 hr. All cells demonstrated greater than 93, 91, and 96% cell 
viability at 24, 48, and 72 hr respectively, for all formulations tested. 
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DISCUSSION 
There is an urgent need for new topical PrEP technologies that can confer the 
sustained-release of active agents, while providing discreet and convenient 
protection against STIs. The emerging technology of biodegradable polymeric 
electrospun fibers offers the potential to fill this unique role. In these studies, we 
evaluated two electrospun fiber delivery platforms, comprised of the polymers, 
PLGA or PLCL, for their ability to prolong the release of TDF in a potential non-
coital delivery vehicle, and to protect against both HIV-1 and HSV-2 infections in 
vitro. Here TDF served as a model antiretroviral drug, as it is only one of two 
agents approved by the FDA to prevent HIV infection. Furthermore, TDF has 
demonstrated antiviral activity against both HIV-1 and HSV-2 in vivo, establishing 
its versatility as a multipurpose active agent. The goal of this work was to 
develop and characterize polymeric electrospun fibers to safely and efficaciously 
provide protection against both HIV-1 and HSV-2 in vitro, as a multipurpose 
prevention platform. For the doses tested in our studies, TDF PLGA and PLCL 
fibers demonstrated enhanced protection, relative to free TDF, against HIV-1 and 
HSV-2 infections for up to 2 wks. 
   The first goal of this study was to determine the formulation of TDF PLGA 
and PLCL fibers that resulted in the most cohesive and well-defined fiber macro- 
and microstructures. During the fabrication of blank PLGA and PLCL fibers, 
several solvents were assessed. We observed that using HFIP and 
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TFE solvents yielded more reproducible PLGA and PLCL fiber morphologies, 
relative to dichloromethane, chloroform, and dimethylformamide (Figure 4). 
These solvents also enabled the incorporation of high weight percent polymer to 
solvent, which is critical to incorporating high concentrations of active agents in 
polymers. Using PLGA and PLCL fibers electrospun with HFIP as our baseline 
platforms, we sought to evaluate the effect of TDF incorporation on fiber diameter 
(Figures 5 and 6).  
 Fiber diameters play a critical role in the release properties of active 
agents incorporated in polymeric vehicles. Previous research has shown that 
decreasing fiber diameter has been correlated to the enhanced release of active 
agents. This is attributed to the increased surface-to-volume ratio, and decreased 
distance necessary for encapsulate diffusion [71, 72]. In our studies, the 
incorporation of TDF resulted in decreased fiber diameters relative to blank fibers 
(Figure 6). The diameters of blank fibers ranged from 1.7 to 2.0 µm, whereas 
TDF fiber diameters ranged from 1.1 to 0.7 µm. In fact, even for the lowest 
concentration (1%) TDF fibers tested, we observed a 50% decrease in fiber 
diameter. This decrease in fiber diameter may be attributed to the charge of the 
active agent, and/or polymer instability resulting from these charge effects. 
Correspondingly, this instability in the polymer solution may result in the polymer 
traveling longer distance/duration during the electrospinning process prior to 
reaching the mandrel, promoting elongation and decreased fiber diameter [73, 
74]. Thus, incorporated active agents can affect the microstructural morphologies 
and diameters of electrospun fibers. 
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 However, the incorporation of antiviral or biological agents has been 
shown to affect fiber diameters in other ways. In previous studies, Tenofovir 
(TFV), a compound less hydrophilic than the fumaric salt form of TFV, TDF (TFV 
solubility = 1.87 mg/mL; TDF salt form (Viread, used in this study) = 13.4 mg/mL; 
Tenofovir disoproxil: 0.71 mg/mL [75, 76]),  was shown to slightly increase fiber 
diameter, though the differences were not statistically significant [77]. In another 
study, an increase in fiber diameter was seen with increased bovine serum 
albumin incorporation. In this study, the increased diameter was attributed to an 
increase in viscosity of the solvent solution prior to electrospinning [78]. In other 
studies, the incorporation of antivirals resulted in the opposite effect on fiber 
diameter. Incorporation of TFV in polyvinyl alcohol polymers resulted in slightly 
smaller diameters, which was attributed to the increased instability described 
above [79]. Finally, some experiments show no change in fiber diameter after 
active agent incorporation. Fibers comprised of the pH-responsive CAP polymer, 
incorporating TDF, showed no change in fiber diameter compared to blank fiber 
counterparts [60]. The compilation of these studies highlights that a variety of 
parameters including solvent choice, polymer selection, solvent-polymer 
interaction, active agent characteristics, and solution viscosity can all contribute 
to the differing microstructural properties of electrospun fibers. 
 After obtaining well-defined and reproducible EFs, we next assessed the 
loading of TDF in PLGA and PLCL fibers as a function of solvent type (HFIP vs. 
TFE) used in the electrospinning process. From these loading studies (Table 1), 
we observed that fibers electrospun with HFIP showed higher encapsulation 
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efficiencies (25% more on average), relative to fibers electrospun with TFE. 
Furthermore, variations in polymer concentration were needed to obtain well-
defined fiber microstructure and high loading efficiency, based on solvent type 
(15 and 12% w/w for PLGA and PLCL in HFIP; 20% PLGA and PLCL in TFE), 
which may be attributed to solvent used during the electrospinning process.
 Despite both HFIP and TFE sharing many characteristics such as high 
polarity and similar molecular structure, there are several key differences that 
may impact fiber properties. First, TFE has a higher dielectric constant [26.1 
(F/m)] compared to TFE [16.7 (F/m)] [80]. This increased charge capacity may 
confer additional instability to TFE solvents during electrospinning, requiring 
more polymer to produce well-defined fiber morphology [81]. Additionally, this 
increase in dielectric constant may result in decreased TDF incorporation, 
causing TDF to localize on or near the fiber surface. HFIP also possesses a 
much lower boiling point (58.2°C) relative to TFE (73.6°C).  Solvents with lower 
boiling points tend to produce more stable fiber morphology due to complete 
evaporation during electrospinning; whereas less volatile (higher boiling point) 
solvents may not fully evaporate from the polymer, causing beaded morphologies 
[82]. These undesirable properties, in addition to the higher polymer 
concentrations required to produce TFE fibers with well-defined fiber 
microstructures and lower loading efficiencies, prompted us to fabricate all 
subsequent formulations with HFIP. 
 Controlled release studies using TDF EFs yielded several interesting 
results (Figure 9).  First, as expected with most polymeric delivery vehicles, all 
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PLGA and PLCL fibers demonstrated a burst release of TDF during the first 24 
hr. The exception was 1% TDF fibers, which released amounts below our limit of 
detection. On average, 0-60% of total incorporated TDF was released by EFs 
within the first 2 days. Overall, the 10% and 20% TDF PLCL fibers showed a 
higher burst release at 1 hr, based on total percent loaded, compared to 
corresponding 10% and 20% TDF PLGA fibers. However, after 24 hr, PLGA and 
PLCL formulations released roughly the same percent of total TDF loaded. 
Based on TDF released per mass polymer, both the 10% and 20% PLCL fiber 
released more TDF at 1 and 24 hours compared with PLGA EFs.  As observed in 
our studies, burst release in nanoscale delivery systems is a common 
phenomenon due to high concentrations of drug localizing on the polymer 
surface [83] . In particular, surface localization may be exacerbated during the 
electrospinning process, due to charge effects between the incorporated drug, 
polymers and solvent. Solution instability during electrospinning due to these 
charge effects, as well as hydrophilic interactions between the solvent and drug 
can also result in agent localization near the fiber surface [74, 84]. Because of 
the increased hydrophobicity of PLCL, a higher percentage of TDF may have 
accumulated on the fiber surface, allowing for higher burst release within the first 
1 hr. 
 In contrast, we observed that all PLGA fibers released higher percentages 
of TDF compared to PLCL fibers, after long-term incubation (4 wk) in SVF. On 
average, PLGA released 20% more of the total incorporated TDF compared to 
PLCL after 4 wk. We attribute this increased long-term TDF release to PLGA 
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being more hydrophilic than PLCL. The increased hydrophilicity of PLGA allows 
for enhanced aqueous solution penetration into the fiber, resulting in increased 
diffusion of TDF from the fiber into the surrounding eluant [56, 85]. We attribute 
this enhanced permeability to water, to the higher amount of TDF released from 
PLGA fibers after the initial burst release phase.  
 In addition to the burst and diffusion release phases, we also noted 
enhanced release of TDF from all PLGA and the 20% PLCL fibers around 21 
days, with PLGA exhibiting the greatest enhancement in release. On average, 
the 20% TDF PLGA and PLCL fibers released 7.2% and 4.8% of TDF between 
the 2 and 3 wk time points, compared to only 3.7% and 0.6% released between 1 
and 2 wk respectively. This enhanced release correlates with the second stage of 
polymer degradation, when matrix degradation enables the release of additional 
encapsulated drug.  
 Other studies using similar polymers yielded equivalent controlled release 
results. In one recent study, TFV was incorporated in PLGA and PCL polymers 
and polymer blends, and controlled release was evaluated for 10 days [63]. 
Similar to our work, PLGA demonstrated greater overall release of drug while 
showing an initial lower burst release. In contrast, PCL released all incorporated 
TFV after 24 hours, while PLGA released only ~20% of incorporated drug during 
this time. Similar burst release of TDF was also observed with 20:80 PCL:PLGA 
fibers, a trend that differed from the prolonged release observed from polymer 
blend incorporation of TFV [63]. Furthermore, several formulations of PCL/PLGA 
blends were fabricated, demonstrating decreased burst release of TFV with 
 62 
 
increasing PLGA concentration [63]. We expect that similar blends may prove 
suitable to tailor the release of TDF, despite its increased lipophilicity.  
 In another study, the antiviral compounds, MVC (Maraviroc) and AZT, 
were encapsulated in PCL, polyethylene oxide (PEO), and poly-L-lactic acid 
(PLLA) polymer blends. Sustained-release from 70:30 PEO/PLLA blends showed 
almost complete release of hydrophilic compounds after 1 hr, due to the extreme 
hydrophilicity and quick degradation of PEO. In contrast, 30:70 PEO:PLLA 
blends exhibited lower burst release and higher sustained-release relative to the 
more hydrophilic 70:30 PEO/PLLA blends.  Additionally, the moderately 
hydrophobic 30:70 PEO/PLLA fibers demonstrated better release profiles relative 
to pure PCL fibers, which released around 95% of incorporated drugs after 1 hr. 
This more efficacious release profile was attributed to the intermediate 
hydrophobicity and crystallinity of PLLA compared to PEO and PCL [62].  The 
hydrophilicity of PEO confers quick degradation in aqueous solutions, resulting in 
burst release; whereas PLCL is highly hydrophobic, causing incorporated 
compounds to localize on the fiber surface, also guaranteeing high burst release. 
The results from these studies are in agreement with our observations that 
polymers comprised of lactic and glycolic acid, relative to the more hydrophobic 
PLCL, exhibit less burst release of moderately hydrophilic compounds. 
 Last, we compared TDF release, based on the percent TDF incorporated 
(1, 10, or 20%) in the fiber. While we expected that 20% TDF fibers would 
release more TDF than 1 or 10% TDF EFs, based on equal polymer mass, as a 
percent of total loading, we observed that 20% TDF PLGA and PLCL fibers 
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released a higher proportion of the total incorporated TDF (86% and 74% 
respectively) over 4 wk, relative to 10% TDF PLGA and PLCL EFs (70% and 
52%).  This phenomenon may be partially due to the decreased fiber diameters 
resulting from higher TDF concentrations, as exhibited by PLCL EFs. Here the 
slightly smaller diameter fibers associated with increased TDF concentration may 
enhance release due to a higher fiber surface area. Another possibility may be 
due to the distribution of TDF within the polymer fibers.  Due to the differences in 
hydrophobicity between PLGA and PLCL, combined with the increased 
concentration of hydrophilic/lipophilic TDF, higher proportions of the drug may 
localize to the fiber surface. Thus, increased TDF concentrations per mass of 
fiber, may also contribute to higher burst release, corresponding with our 
observations 
 After characterizing these fibers, TDF EFs were evaluated for their 
potential to protect against HIV and HSV-2 infections in vitro (Figures 10-13). In 
these studies, TDF EF eluates of up to 2 wk, conferred protection against HIV, 
particularly for the 10 and 20% formulations (Figure 10); whereas HSV-2 
inhibition was only achieved using the 1 or 24 hr release eluate (Figure 11). One 
factor that we believe contributes to this lack of efficacy associated with longer 
release times is the difference in TDF potency against HSV-2 and HIV-1. While 
TDF is efficacious against both HSV-2 and HIV-1, TDF is much less efficacious 
for HSV-2 (IC50 = 16 µg/mL) relative to HIV (0.06 µg/mL). Based on the release 
profiles of the 20% TDF PLGA and PLCL polymers, we expect that we would 
need approximately 15-20 mg fiber to provide 1 mg of TDF release (over one 
 64 
 
month), and corresponding efficacy after 2 wk release. To account for this and in 
concurrent work, correspondingly increased amounts of TDF fibers will be used 
to assess HSV-2 efficacy after longer durations of fiber release.  These estimates 
are within the dosing we envision for in vivo studies, in which similar studies have 
delivered a range of 0.2 to 0.7 mg/mL TDF per day within the murine 
reproductive tract to prevent HIV/HSV-2 infections [50, 51].  
 In addition to the increased TDF concentration needed to prevent HSV-2 
relative to HIV-1 infections, the duration of fiber exposure to eluate likely impacts 
the potency of TDF released from the fibers. This is clearly observed in our 
efficacy studies where the administration of 1 and 24 hr TDF fiber eluates 
demonstrated similar efficacy to free TDF; whereas, after 1 wk of release, TDF 
fiber eluates exhibited greater efficacy against HIV-1, relative to free TDF (Tables 
2 and 3). Moreover, after 2 wk, the IC50s of both TDF eluates and free TDF 
increased; with the potency of free TDF more dramatically affected (Table 3).  
 One factor validating the improved IC50s of TDF fibers, relative to free 
TDF with respect to time, is that TDF is known to crystallize and degrade in 
aqueous environments both in vitro and in vivo [50, 85-87] . While, increasing the 
stability of active agents is a benefit of utilizing delivery platforms such as fibers, 
even TDF fibers exhibited decreased efficacy against HIV-1 after 1 to 2 wk in 
eluate (Table 3). Relative to each other, PLGA fibers showed a more rapid 
decrease in efficacy relative to PLCL fibers.  This may be attributed to an 
increase in polymer hydrophilicity with corresponding release of TDF from PLGA 
fibers (Figure 9), leading to longer drug exposure in the aqueous environment. 
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Additionally, long-term incubation of PLGA releases lactic and glycolic acid, 
resulting in a localized decrease in pH. Correspondingly, acidic conditions are 
known to enhance TDF degradation and may contribute to the decreased 
efficacy of TDF incorporated in PLGA fibers [87]. Thus, the longer an 
incorporated drug remains within the polymer under physiological pH, the longer 
it will retain efficacy. For future work this suggests that utilization of a different 
polymer or polymer blends may more optimally maintain active agent activity for 
durations exceeding 1 wk. Finally, the safety of both TDF PLGA and PLCL fibers 
was assessed after administration to vaginal and cervical cells.  Our studies 
demonstrate that all cell lines had greater than 91% viability after fiber 
administration from 1 to 3 days (Figure 14). This is in agreement with our 
expectations; given that both polymers and TDF are FDA-approved (PLCL is a 
derivative of the FDA-approved polymer PCL). Based on these in vitro results, 
we expect to see similar safety profiles from fibers in tissue mimic and in vivo 
testing.  This high biocompatibility, sustained-release, and demonstrated efficacy 
of PLGA and PLCL fibers warrant their investigation in immunological, 
pharmacokinetic/dynamic (PK/PD), and efficacy studies in vivo. 
 In parallel with advancing these formulations for in vivo study, our 
laboratory currently seeks to enhance the efficacy of our electrospun fibers 
against multiple STIs. Other polymer formulations are currently being evaluated 
to enhance sustained-release properties of antivirals and biological agents. The 
use of different solvents (or combination of) might confer enhanced loading of 
drugs of interest. However, more importantly, different polymers or polymer 
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blends might reduce the initial burst release of incorporated products while 
simultaneously optimizing long-term release. Furthermore, the development of 
multilayered and coaxially-spun fibers may also provide a platform suited for the 
delivery of multiple compounds with sustained-release profiles. Finally, surface 
modification of fibers or nanoparticle incorporation might offer alternative 
avenues to enhance or complement the prophylactic potential of these fibers. 
 Another potential route to complement the efficacy of our fibers is the 
incorporation of active agents with other mechanisms of action.  The 
incorporation of novel non-ARV agents may avert some of the effects of toxicity 
and antiviral resistance recognized as impediments to long-term ARV use. One 
promising biologic that may fulfill the needs of safety and potency against 
multiple STIs is the antiviral lectin, griffithsin (GRFT), which has previously 
demonstrated efficacy against both HIV-1 and HSV-2.  Furthermore, GRFT can 
be covalently bound to the fiber surface, acting as an adhesive scaffold to bind to 
and inactivate virus, in addition to its sustained-release potential. While more 
challenging, the incorporation of short interfering RNAs (siRNAs) may provide 
genetically-targeted mechanisms to inhibit viral and/or host targets, such as 
CCR5, to further enhance protection, while minimizing off-target effects. The 
incorporation of GRFT and other biologics in EFs highlights the seemingly 
limitless potential of EFs as novel topical delivery vehicles for microbicide 
applications.  
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SUMMARY AND CONCLUSIONS 
 There is an urgent need to develop new and alternative sustained-release 
technologies to prevent HIV-1 and HSV-2 infections. To address these needs, we 
fabricated PLGA and PLCL electrospun fibers, and compared the loading and 
sustained-release properties of these fibers, using TDF as a model antiviral. Both 
PLGA and PLCL fibers exhibited sustained-release for up to 4 weeks and 
provided complete protection against both HIV-1 and HSV-2 infections in vitro. 
Both short- (1 and 24 hr) and long-term (1 and 2 wk) protection were achieved 
against HIV-1; whereas short-term protection (due to fiber dosing) was achieved 
against HSV-2 in vitro. Additionally, TDF fibers demonstrated significantly 
enhanced efficacy against HIV-1, relative to free TDF, after long-term release of 
1 and 2 wk.  Lastly, vaginal and cervical cells exposed to TDF PLGA and PLCL 
fibers showed high viability, after up to 3 days administration, demonstrating their 
safety in vitro. 
 Comparing the attributes of PLGA and PLCL TDF EFs, PLGA initially 
appears to be a more promising candidate compared to PLCL, based on its 
improved sustained-release profile.  PLGA possesses a lower burst release as 
well as increased long-term release of TDF relative to PLCL. However, upon 
further investigation, PLCL EFs maintained the stability of TDF for longer 
durations in vitro. However, as both formulations demonstrated efficacy against
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HIV and HSV-2 in vitro, future testing may reveal both fiber formulations to be 
equally efficacious in vivo.  
 This work serves as the foundation for our future work. Using the 
information obtained here, we seek to further enhance the efficacy and delivery 
duration of small molecule antivirals and biologics from EFs by utilizing a variety 
of encapsulants and polymer blends. Additionally, future in vivo work with our 
TDF fibers is planned to demonstrate fiber efficacy and safety in a murine model 
of infection. We predict that these, or similar electrospun fibers will confer long 
lasting and sustained protection against both HIV and HSV-2 infections.
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